A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.
- DOI
- 10.1016/j.tjpad.2025.100337
- Published
- 2025 Nov
- Container
- The journal of prevention of Alzheimer's disease
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.tjpad.2025.100337,
title = {A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.},
author = {Greeley D and Nash M and Herskowitz B and Kim F and Rock J and Prins N and Kim S and Xi T and Busam JA and Tete B and Choung JJ and Sha SJ},
year = {2025},
journal = {The journal of prevention of Alzheimer's disease},
doi = {10.1016/j.tjpad.2025.100337},
url = {https://doi.org/10.1016/j.tjpad.2025.100337}
}RIS
TY - JOUR TI - A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease. AU - Greeley D AU - Nash M AU - Herskowitz B AU - Kim F AU - Rock J AU - Prins N AU - Kim S AU - Xi T AU - Busam JA AU - Tete B AU - Choung JJ AU - Sha SJ PY - 2025 JO - The journal of prevention of Alzheimer's disease DO - 10.1016/j.tjpad.2025.100337 UR - https://doi.org/10.1016/j.tjpad.2025.100337 ER -
APA
D, G., M, N., B, H., F, K., J, R., N, P., S, K., T, X., JA, B., B, T., JJ, C., & SJ, S. (2025). A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2025.100337
Source records
- pubmed · retrieved 2026-09-25T18:49:05.981Z